Telotristat Etiprate · Xermelo, LX1606

What is Telotristat Etiprate?

Telotristat etiprate is an orally bioavailable small-molecule inhibitor of tryptophan hydroxylase that is converted to its active metabolite telotristat. It reduces peripheral serotonin production by blocking the rate-limiting enzyme in serotonin biosynthesis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as

Xermelo, LX1606, LX-1032 HIPPURATE, LX-1606 HIPPURATE

Drug type

Small molecule

Targets

tryptophan hydroxylase (TPH1)

Mechanism

Inhibitor of tryptophan hydroxylase (TPH1)

Pathways

serotonin biosynthesis

Therapy area

Oncology

Developer

Tersera

In trials of

LXRX

FDA status

Approved as Xermelo (February 28, 2017), NDA208794 · FDA label

UNII

3T25U84H4U

✅ FDA-approved uses

• Carcinoid syndrome diarrhea

From the indications section of the FDA label (version of Aug 6, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Carcinoid Syndrome

Sources

• FDA label (DailyMed)
• FDA label Xermelo (2026-08-06), indications
• NCI Thesaurus
• ClinicalTrials.gov NCT02026063

Updated Oct 3, 2026.